Index

Index

Abbott Laboratories, 149, 196	generic applied research, 312
Abello Co. (F. R.G.), 130	international comparisons, 317
acquired immunedeficiency syndrome (AIDS), 125, 132	issues and options, 325
Advanced Genetic Sciences, Inc., 82	National Institutes of Health, 310, 323
Agent Orange, 222	National Science Foundation, 310
Agricultural Genetics (U.K.), 71, 82, 320, 425	USDA, 311, 323
Ajinomoto Co., 83, 131, 196, 197, 505	Baxter Travenol Laboratories, 134, 196
Allied Corp., 82	Baxter, William, Assistant Attorney General, 436
American Association for the Advancement of Science,	Bayer Co., 83
309	Beckman Instruments, 87, 88
American Association of Universities, 421	Becton Dickinson Co., 145
American Cancer Society, 123	Beecham Co. (U.K.), 75
American Commercial Co., 87	Bell Laboratories, 308, 532
American Cyanamid, 80, 81, 167	Berkey Photo, Inc. v. Eastman Kodak Co., 440
American Hospital Supply, 196	Bethesda Research Laboratories, 84, 199
American Society for Engineering Education, 341	bioelectronics, 7, 253-256
Amgen Co., 80, 130, 149, 167	biochips, 254
Amicon Co., 54, 88	biosensors, 253
analysis, framework for, 263-266	future research, 256
competitiveness in biotechnology, factors influencing,	bioengineering, novel techniques, 3, 4, 25
263	Biogen Co., 99, 101, 122, 133, 134
firms commercializing biotechnology, 265	Bio Logicals, 85, 90
Anheuser Busch, 102, 247	Biopol [®] , 211
animal agriculture industry, 6, 79-81, 162-171	bioprocessing separation and purification
animal nutrition and growth promotion, 167	instrumentation, 88
commercial aspects of biotechnology, 169	bioprocess technology, 5, 44-57
diagnosis, prevention, and control of animal diseases,	biocatalyst, 51
162	continuous bioprocessing, 48-50
animal vaccines, 163, 164	culture of higher eukaryotic cells, 55
monoclinal antibody diagnostic products, 162	essentials, 46
future research, 186	monitoring and associated instrumentation, 52
genetic improvement of animal breeds, 168	priorities for future research, 56
Animal Vaccine Research Corp., 99	processing modes, 47
Applied Biosystems, 84, 87, 148	raw materials, 51
antitrust law, 435-449	separation and purification of products, 54
biotechnology licensing agreements, 447	steps in, 46
biotechnology research joint ventures, 446	BioSearch Co., 84, 87
European Economic Community, 441	Biotechnica International, 80, 82
findings, 448	Bio-Technology General Corp., 80, 82, 167
issue, 449	Biotechnology Industrial Associates, 99
relevant U.S. and foreign antitrust laws, 438	Biotechnology Institute and Studies Centre Trust, 320
research joint ventures, 435	Blanch, Harvey, University of California, Berkeley, 44,
technology licensing, 437	576
ARCO, 82	Boehringer Ingleheim (F. R.G.), 75
Arkansas, 384	Boehringer Mannheim (F. R.G.), 82, 199
Armour Pharmaceutical, 134	Bok, Derek, president, Harvard University, 421
Aronson v. Quick Point, 399	Brazil, 527
Atlantic Richfield Co., 228	Bristol Myers, 102
Australia, 523	British Technology Group, 320
automated DNA and peptide synthesizers, 86	Budapest Treaty on the International Recognition
	of the Deposit of Microorganisms for the Purpose of
Bailey, James, California Institute of Technology, 44	Patent Procedure, 389
Baltimore, David, 575	Burroughs-Wellcome (U.K.), 130, 171
basic and applied research, U.S. Government funding of,	0.1. 0.494
307-328	Calgene Co., 421
Department of Defense, 311	Cambridge Reports, Inc., 496, 497
Department of Energy, 311, 323	Canada, 525
findings, 323	Canadian Development Corp., 247

cancer treatment, 126	future research, 230
cell fusion, 3, 4, 174	grease decomposition, 223
Celltech (U.K.), 71, 87, 125, 200, 320, 425	heavy metal contamination, control of, 221
Centocor Co., 92, 144	microbial enhanced oil recovery, 228
Cetus Corp., 80, 82, 90, 92, 99, 101, 122, 148, 166	microbially produced compounds in oil wells, use of,
Chiron Corp., 80, 137	229
Ciba Geigy Co., 74, 75	microbiological mining, 226-228
City of Hope Medical Center and Research Institute, 42, 121	commercial aspects of biotechnology in, 228 concentration of metals, 227
Cohen-Boyer patent, 389, 390, 411, 478	mineral leaching, 226
Collaborative Research Co., 84, 200	microorganisms in oil wells, use of, 229
Columbia University, 421	organic micropollutants, control of, 220
commodity chemicals and energy production, 237-249	slime control, 223
biomass resources, 239	toxic waste treatment, 222
lignocellulose, 241	treatment of nontoxic liquid and solid wastes, 217
conversion of biomass to commodity chemicals, 242	•
hydrolysis, 243	Enzo Biochemical, 148, 149
pretreatment, 242	E. R. Squibb, 121
future research, 248	established U.S. companies, 99-103
international research activities, 247	collaborative ventures with U.S. NBFs, 103
microbial production, 244	investments in biotechnology, 99
Commission of European Communities, 441	role in U.S. competitiveness in biotechnology, 102
Commodity Control List, 455, 456	European Economic Community (EEC), 358, 365, 366,
companies commercializing biotechnology	435, 441, 461, 551, 556, 559
in the United States, 67-70	European Molecular Biology Laboratory, 89
Congress:	European Patent Convention, 393, 395, 397, 564
Subcommittee on Investigations and Oversight, 492	European Patent Office, 393
Subcommittee on Science, Research, and Technology, 492	Florida State University, 421
congressional interest, 22, 325, 347, 376, 403	Fluor Co., 101
Connaught Laboratories, 134	food additives, 6
Cooney, Charles, MIT, 44	France:
Coordinating Committee for Multilateral Export	antitrust laws, 444
Controls, 455	Biotechnology Mission, 477
Cornell University, 244	competitiveness, 8, 9
Corning Glass, 99°	environmental control, 557
Creative Biomolecules, 84, 87	export controls, 459
Cruachan Chemicals Co., 87	financing and tax incentives, 519
Cutter Laboratories, 144	funding of biotechnology, 317
	government funding of basic and applied research,
David, E., 413	519
definitions of biotechnology, 3, 503	government targeting policies, 477, 518
Demain, Prof. Arnold, 344	intellectual property law, 564 industry, 518
Demon Biotech Corp. (U.S.), 43 Diamond Shamrock, 81, 99	Institut Pasteur, 140, 322, 339, 343
Diamond Shalliotk, 61, 55 Diamond v. Chakrabarty, 386, 387, 391, 392, 394, 400,	investment control laws, 461
403	law of trade secrets, 569
Du Pent, 82, 99, 102	Ministry of Health, 369
Du I ciit, 62, 66, 162	Ministry of Research and Industry, 477
Eastman Chemicals, 202	National Biotechnology Committee, 478
Ecogen, Inc., 82	National Center for Scientific Research, 343, 426
Elf Aquitaine (France), 12, 75	National Control Commission, 359, 554
Elf-Bioindustries, 76	patent law, 565
Elf-Bioresearch, 76	personnel availability, 339, 520
Eli Lilly & Co., 54, 80, 92, 99, 102, 121, 122, 127, 130,	pharmaceutical industry, 75
150, 168, 446	plant breeders rights, 570
environmental applications, 217-230, 555	R&D SUPPOrt, 482
commercial aspects of biotechnology in, 224	rDNA research control, 359, 554
conventional wastewater treatment process,	regulation of biotechnology products, 369
improvement of, 219	research, 322

undergraduate and graduate education, 343 Goodman, Howard, 575 university/industry relationship, 426, 520 Gore, Cong. Albert, 419, 421, 495 worker health safety, 560 grants, 347 Fuqua, Congressman Don, 315 Green Cross Co., 133, 135, 137, 481 Guide to Research Joint Ventures, 439 Gaden, Elmer, University of Virginia, 44 **Gulf Universities Research Consortium, 421** G. D. Searle, 102 Hagiwara Institute of Health, 420 Gellman Research Associates, Inc., 91 Harvard University, 412, 414, 417, 421 Genencor, 99, 103, 200 health, safety, and environmental regulation, 355-378 Genentech (U.S.), 42, 53, 66, 80, 85, 90, 92, 93, 95, 96, 98, 99, 101, 121, 127, 128, 133, 142, 150, 164, 167, environmental regulation, 371-373 findings, 374 376, 384 issue and options, 376 generic applied research, 8, 14 rDNA research guidelines, 356 Genetica Co., 76 Genetic Sequence Data Bank (GENBANK), 89 approved requirements, 358 containment requirements, 358 Genetics Systems Co., 92, 144 effect on competitiveness, 359 Genex Corp., 80, 84, 93, 98, 99, 101, 133, 167, 197, 200 enforcement, 359 Georgetown University Medical Center, 89 German Cartel Office, 443 scope, 357 German Research Society, 342, 424 regulation of biotechnology products, 359 European Economic Community, 365-370 German Society for Chemical Engineering, 424, 510 Germany, Federal Republic of @. R.G.): United States, 360-365 worker health and safety regulation, 373-374 antitrust laws, 442 Henkel Co., 202 competitiveness, 8, 9, 424 Hewlett-Packard, 53, 84, 88, 90 Control Commission for Biological Safety, 552 **Dangerous Industrial Substances Committee**, 559 Hoechst (F. R.G.), 12, 74, 83, 122, 130, 343, 417, 510, 575 environmental control, 556 Hoffmann-La Roche, Inc. v. Golde, 384 export controls, 458 Hoffmann-La Roche (Switzerland), 12, 74, 75, 92, 125, Federal Environmental Agency, 556 130, 420 Federal Health Office, 366 Human Services Research, 91 Humulin", 446, 538 Federal Ministry of Science and Technology (BMFT), 18, 317, 338, 424, 476, 478, 481, 510, 511 financing and tax incentives for firms, 511 ICI (U.K.), 12, 75, 204, 211 government funding of basic and applied research, Idaho, 384 317, 511 Idaho National Engineering Laboratory, 228 impact on reseach community, 25 government targeting policies, 476, 510 intellectual property law, 395, 396, 564 Industrial Biotechnology Association, 421 law of trade secrets, 568 industrial development of, 5, 9 Integrated Genetics Co., 149 Max Planck Society, 342, 511 Ministry of Education, 476 intellectual property law, 383-405 **NBFs**, 71 evaluation of effectiveness, 400 foreign countries, 401 organization of basic and applied research, 318 United States, 400 patent law, 565 pharmaceutical industry, 74, 75 findings, 401 plant agriculture industry, 82 issue and options, 403 United States, 384-393 plant breeders rights, 569 personnel availability and training, 337, 512 law of trade secrets, 384 R&D SUPPOrt, 481 patent law, 385 rDNA research control, 359, 552 plant breeders' rights statutes, 392 U.S. and foreign, comparison of, 393 regulation of biotechnology products, 366 patent law, 393 Risk Financing Society, 512 specialty chemicals industry, 83 plant breeders' rights, 399 Society for Biotechnology Research, 82, 318, 319, 478 trade secret law, 398 Intelligenetics Co., 84 summary of biotechnolo~, 510 undergraduate and graduate education, 342 international competitiveness factors: analysis of, 8-10 university/industrial relationships, 423, 512 worker health safety, 559 antitrust laws, 18 Gist-Brocades NV, 199 financing and tax incentives for firms, 12 Glaxo (U.K.), 12, 75 government funding of basic and applied research, 13 Goodfield, June, 495 government targeting policies, 19

health, safety, and environmental regulation, 15	organization of basic and applied research, 318
intellectual property law, 16	C)saka University, 423
personnel availability and training, 14	patent law, 571
public perception, 20	personnel availability, 337, 508
technology transfer, investment and trade, 18	personnel engaged in rDNA R&D, 506
university/industry relationships, 17	pharmaceutical industry, 76, 77, 78, 79
International Congress of Plant Tissue and Cell Culture,	plant agriculture industry, 83
179	plant breeders' rights, 572
International Genetic Engineering, 82	R&D SUPPOI't, 480
international technology transfer, investment, and trade,	rDNA research control, 359, 554
453-470	rDNA technology expenditures, 505
export controls and biotechnology, U.S. and foreign,	regulation of biotechnology products, 370
455	Science and Technology Agency, 86, 317, 341, 423,
findings, 468	480, 506
issue, 470	specialty chemicals industry, 83
patent law provisions, 459	summary of biotechnology, 505
compulsory licensing, 460	support firms, 84, 86
national security restrictions, 459	targeting policies, 475
regulation of technology imports and foreign	Tokyo University, 341
investment, 461	trade barriers, 464
trade barriers affecting biotechnology products, 463	transnational training, 343, 344
trade laws, 467	Tsukuba Science City, 481
International Union for the Protection of New Varieties	undergraduate and graduate education, 341
and Plants, 392	university/industry relationships, 422, 508
Intervet Corp., 166	University of Tsukuba, 341
Israel, 524	worker health safety, 561
	Japanese Cancer Institute, 131
Japan:	Johns Hopkins University, 412, 414, 417
amino acids, 196	Johnson & Johnson, 149, 254
antitrust laws, 445	
Associated Finance Corp., 507	KabiGen AB, 127, 128
bioprocessing, 12	KabiVitrum AB, 128, 133
Biotechnology Forum, 478	Kansas, 384
biotechnology projects, 318	Keidanren survey, 76, 77, 79, 344, 345
competitiveness, 7, 9, 11, 21	Kelco Co., 210
Council for Science and Technology, 475	Kennedy, Donald, 308
diversification of chemical, food processing, and textile	Kohler, George, 39
and pulp processing companies into	Kyowa Hakko Co., 83, 196, 197
pharmaceuticals, 76, 77	
environmental control, 588	
export controls, 458	Lawless, E. W., 490
Fair Trade Commission, 445	legislation:
financing and tax incentives, 13, 507	Act Against Restraints of Competition (F. R.G.), 442
funding of biotechnology, 317	Act Concerning Prohibition of Private Monopoly and
intellectual property law, 393, 396, 397, 402, 571	Maintenance of Fair Trade (Japan), 445
investment control laws, 462	Act No. 77-806 (France), 444
joint ventures in pharmaceutical applications of	Agricultural Chemicals Law (Japan), 464
biotechnology, 78	Basic Law for Environmental Pollution Control (Japan),
Keidanren (Japan Federation of Economic	558
Organizations), 76, 77, 79	Chemicals Act (F. R.G.), 556
law of trade secrets, 572	Chemicals Control Law (France), 557
Ministry of Agriculture, 317, 476, 506	Chemical Substances Control Law (Japan), 558
Ministry of Education, 423, 555	Clayton Act, 438, 439
Ministry of Finance, 445	Clean Air Act, 556
Ministry of Health, 77, 37o	Clean Water Act of 1977, 555
Ministry of International Trade (MITI), 9, 12, 78, 83,	Competition Act of 1980 (U.K.), 443
86, 317, 341, 423, 445, 458, 476, 479, 481, 506, 507,	Control of Pollution Act of 1974 (U.K.), 557
558	Export Administration Act, 455, 456, 470
New Technology Development Fund, 423, 481	Fair Trading Act (U.K.), 443
Nikkei Sangyo <i>Shimbun</i> (Japan Industrial Daily), 77, 79	Federal Cartels Act (Switzerland), 444
	· ·

Federal Food, Drug, and Cosmetic Act (FFDCA), 360, 361, 362, 363, 365, 376, 377 Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA), 365, 555 Federal Trade Commission Act, 438 Foreign Exchange and Foreign Trade Control Law (Japan), 458, 462 Federal Water Pollution Control Act, 555 Health and Safety at Work Act of 1974 (U.K.), 560 Health Research Education Act of 1983, 495 H.R. 3577, 405 Import, Export, and Customs Powers Act (U.K.), 458 Industrial Safety and Health Law (Japan), 561 **International Emergency Economic Powers Act, 458** Law on the Reform of Drug Legislation (F. R.G.), 366 Marine Protection, Research and Sanctuaries Act of 1972, 556 Medicines Act of 1968 (U.K.), 367 Occupational Safety and Health Act of 1970, 374, 558 Patent Act of 1977 (U.K.), 566 Pharmaceutical Affairs Law (Japan), 370, 464 Plant Patent Act of 1930, 392, 399, 400, 404 Plant Variety Protection Act, 392, 399, 400, 404, 460 Price Ordinance No. 15-1483 (France), 444 Public Health Service Act, 360, 361 Public Law 96-517, 411, 419 Research Association Law (Japan), 445 Sherman Act, 438 Small Business Innovation Development Act, 313 Solid Waste Disposal Act, 556 Swiss Patent Act, 566 **Tariff Act of 1930, 467** Toxic Chemicals Law (Japan), 464 Toxic Substance Control Act (TSCA), 365, 371, 372, Trade Act of 1974, 453, 466, 469 Virus, Serum, Toxin Act of 1913, 363, 365, 377 Water Protection Act (Swiss), 557 Lilly, Malcolm, 342 local efforts to promote biotechnology development in United States, 26 Los Alamos National Laboratory, 89 Lubrizol Co., 101 Massachusetts General Hospital, 144, 343, 417, 418, 419, Massachusetts Institute of Technology (MIT), 344, 412, 414, 417, 418, 421, 575 Max Planck Institute for Biotechnology, 164 Max Planck Institute for Plant Research, 82, 425 Merck Co., 137, 201 messenger RNA (mRNA), 34 Mexico, 238 Michigan State University, 418, 576 Microelectronics Computer Corp., 447 Militarily Critical Technologies List, 457

Millipore Co., 54, 88

Mitsubishi Chemical Co., 76, 133, 505

Milstein, Cesar, 39 Minnesota, 384

Mitsui Toatsu Chemicals, 198 Miyoshi Oil and Fat Co., 206 Molecular Biology Institute, 418 Molecular Genetics, Inc., 80, 82, 166, 167 monoclinal antibodies (MAbs) technology, 5, 8, 25, 38-43 industrial uses for, 43 large-scale production of, 42 preparation, 40 sheep red blood cells (SRBCS), 39 and rDNA technology, 42 Monsanto, 80, 82, 99, 101, 167, 197, 417, 574 Motulsky, A. G., 498 multidisciplinary nature of biotechnology, 25 McDonnell Douglas, 54 McTaggart, John, 88 National Academy of Sciences, 26, 332 National Aeronautics and Space Administration, 54, 123, 314, 315 National Assessment of Education, 496 National Biomedical Research Foundation, 89 National Cancer Institute, 123 National Council of Churches, 493 National Institutes of Health, 84, 89, 119, 123, 127, 151, 307, 308, 310, 312, 313, 335, 343, 348, 357, 358, 360, 371, 372, 418, 489, 491, 551 National Institute of Occupational Safety and Health, 373 National Research Council, Canada, 244 National Science Foundation, 91, 228, 247, 309, 310, 312, 313, 315, 316, 327, 335, 347, 348 Netherlands, 522 new biotechnology firms (NBFs), 6, 7 11, 12, 13, 65, 66, collaborative ventures with established foreign companies, 108 commercial pursuits of, 93 emergence and financing, 92 future prospects, 95 joint ventures, NBFs and established firms, listing of, 104 licensing, 454 role in U.S. competitiveness, 97 New Drug Application (NDA), 361 New England BioLabs, 84, 199 New England Monoclinal Resources, 94 New York University (NYU), 142 Nippon Oil and Fat Co., 206 Nippon Zeon Co., 86 Norden Co., 80 Norman Research Institute, 423 North Carolina Biotechnology Center, 26, 75, 418 Notice of Claimed Investigational Exemption for a New Drug (IND), 360 Novo Industri A/S, 121, 199, 247 Nucleopore Co., 54, 88 Nucleotide Sequence Data Library, 89

Occupational Safety and Health Administration (OSHA), 374, 558

Nucleic Acid Sequence Database, 89

Oppenheimer & Co., 94 Organization for Economic Cooperation and Develop- ment, 71	disease-suppressive and growth-regulating micro- organisms, 184 foreign, 82
organization of report, 27	future research, 186
Organon Co., 130	methods of plant cell culture, 175
OTA/NAS survey of personnel needs of firms in the	microbially produced insecticides, 183
United States, 547	nitrogen fixation, 181
D : C :: 400	photosynthetic efficiency, 180
Paris Convention, 460	plant growth rate, 180
Paul Ehrlich Institute, 366	plant-produced pesticides, 181
Perkin Elmer Co., 88	primary plant products, 178
Perlmann, David, 336	secondary compounds from plants, 179
personnel and training, 331-350	specific plant characteristics, improvement of, 174
availability of personnel in the United States, 335	United States, 81
categories of technical expertise, 333-335	uses of micro~rganisms for crop improvement, 181
findings, 345	vector construction and transformation, 176
issues and options, 347	P-L Biochemical Co., 84, 87, 199
labor force, size and growth of, 332	Pope John Paul II, 493
personnel availability in other countries, 336	President's Commission for the Study of Ethical Prob-
secondary school education, U.S. and other countries, 339	lems in Medicine and Biomedical and Behavioral Research, 493, 494, 495
translational training, 343	public perception, 489, 499
undergraduate and graduate education, U.S. and other	arguments raised, 492
countries, 340	difficulties in weighting the risks, costs, and benefits,
Petroferm, 229	494
Pfizer Co., 102, 229	factors influencing, 490
pharmaceutical industry, 72-79, 119-152	findings, 499
antibodies, 143	implications for competitiveness, 497
blood products, 131-136	influence of the media, 495
antihemophilic factor (AHF), 133, 134	issues, 499
	•
human serum albumin (HSA), 132	surveys, 496
thrombolytic and fibrinolytic enzymes, 134	On: dal Ca 04
commercial aspects of biotechnology, 150	Quidel Co., 94
DNA hybridization probes, 148-149	DNIA to de de Conta d
drug delivery systems, 123	recombinant DNA technology (rDNA), 3, 4, 5, 25
foreign companies, 74	environmental regulation, 355
future research, 151	guidelines, environmental laws, and regulation of
human growth hormone, 127	health and safety, 550-561
interferon gene cloning projects, companies involved,	in industrial processes, 37-38
128	preparing rDNA, 36, 37
lymphokines, 130	structure and function, 33-36
melanocyte stimulating hormone (MSH), 128	Reckitt & Colman (U.K.), 130
monoclinal antibodies, 143-147	regulation of worker health and safety, 558
diagnostic products, 144	research funding, U.S. Government, 14
preventive and therapeutic products, 147	Rhone Poulene (France), 12, 74, 75, 76
neuroactive peptides, 128	Roussel Uclaf Co., 130
proteins being developed with rDNA technology, 129	
R&D expenditures, 75	Salt Institute, 99
regulatory proteins, 120	Sandoz Co., 74, 130
human insulin, 120	Sanofi Co., 75
interferon, 122-126	Saudi Arabia, 238
top 20 U.S. and foreign companies, 73	Schering AG (F.R.G.), 75, 84
U.S. companies, 72	Schering-Plough (U.S.), 150
vaccines, 136, 143	Science 71"mes, 496
bacterial disease vaccines, 139	Scripps Clinic and Research Foundation, 134
parasite disease vaccines, 140	SDS Biotech Corp., 81
viral disease vaccines, 136	Shell, 82
Pharmacia, 88	Showa Denko, 81, 83
plant agriculture industry, 6, 172-186	SmithKline Beckman, 80
	Soviet Acquisition of Western Technology, 458
commercial aspects of biotechnology, 185	SOVICE ACQUISITION OF WESTERN TECHNOLOGY, 438

specialty chemicals industry, 6, 83-84, 195-212	Takara Shuzo Co., 86
amino acids, 195-198	Takeda Co., 76, 130
aspartic acid, 198	Taniguchi, Dr. Tadalsugi, 131
g]utamic acid, 196	targeting policies in biotechnology, 425
lysine, 197	findings, 482
methionine, 195	industrials' role in policy formulation, 478
phenylalanine, 198	issue, 483
tryptophen, 197	policy goals, 479
aromatic specialty chemicals, 208	policy implementation, 480
commercial aspects of biotechnology in, 211	timing and coordination, 475
complex lipids, 205-207	Techniclone Co., 94
fatty alcohols, 206	Toray Industries, 197, 505
microbial oils, 206	Transgene (France), 71
sopherolipids, 207	Treaty of Rome, 441
enzymes, 198-200	**** * 1 1
future research, 212	U.N. Industrial Development Organization, 26
polysaccharide copolymers, 209	United Kingdom:
single-en protein (SCP), 202,205	antitrust laws, 443
production plants, 204	biochemical supply, 86
steriods, 207	bioprocessing, 12
vitamins, 200-202	biotechnology centers, 319
Speywood Laboratories, 134	Center for Applied Microbiology, 320
Stanford Research Institute, 308	competitiveness, 8, 9, 425
Stanford University, 411, 412, 414, 415, 418, 420	Department of Industry, 477, 478, 482
Sumitomo Chemical Co., 76, 505	environmental control, 557
support firms, U.S. and foreign, 84-91	export controls, 458
product areas:	financing and tax incentives, 514 Genetic Manipulation Advisory Group, 358, 515, 553,
biochemcial reagents, 85 instrumentation, 86	
software, 89	560 government funding of basic and applied research,
Sweden, 520-522	312, 513
Swiss Serum and Vaccine Institute, 140	government targeting policies, 477, 513
Switzerland:	Health and Safety Executive, 358
antitrust laws, 444	Imperial College, 342, 425
Commission for Experimental Genetics, 554	industry, 513
Commission for the Encouragement of Scientific	intellectual property laws, 399, 564
Research, 322	law of trade secrets, 568
competitiveness, 8, 9	Medical Research Council, 338, 425
environmental control, 557	Monopolies and Mergers Commission, 443
export controls, 459	patent law, 565
Federal Institute of Technology, 320, 426	plant agriculture industry, 82
Federal Office of Public Health, 37o	plant breeders rights, 570
government funding of basic and applied research,	organization of basic and applied research, 319
517	personnel availability and training, 338, 514
industry, 516	R&D SUPPOI't, 482
intellectual property laws, 564	rDNA research control, 358, 552
Intercantonal Convention for the Control of	regulation of biotechnology products, 367
Medicaments, 370	Science and Economic Research Council, 338,425
law of trade secrets, 569	summary of biotechnology, 512
patent law, 565	financing, 514
personnel availability, 338, 517	funding, 513
plant breeders rights, 570	industry, 513
rDNA research control, 554	personnel, 514
regulation of biotechnology products, 37o	targeting, 513
research, 320	undergraduate and graduate education, 342
tax incentives, 517	university/industrial relationship, 425, 515
summary of biotechnology, 516	University Grants Committee, 342
university /indudstry relationship, 426	worker health safety, 560
worker health safety, 560	United States v. Penn~lin Chemical Co., 439
Synagogue Council of America, 493	University Genetics, 148

University/industry relationships, 411-427	U.S. Department of Justice, 436, 438, 439, 440, 441
commingling of funds, 419	U.S. Department of Transportation, 314
consulting arrangements, 416	U.S. Environmental Protection Agency (EPA), 183, 314,
effectiveness in biotechnology, 413	360, 371, 372
guidelines for industrial sponsorship, s77	U.S. federally funded research in biotechnology, 310-312
industrial associates programs, 417	U.S. Federal Trade Commission, 438
intellectual property, 419	U.S. firms commercializing in biotechnology, list of, 542
issue, 429	U.S. Food and Drug Administration (FDA), 16, 81, 121,
Pajaro Dunes Conference, 578	150, 355, 376, 377
patent rights and commingling of research funds, 579	Bureau of Foods, 362
private corporations, 418, 576	National Center for Devices and Radiologic Health, 362
research contracts, 417	Office of New Drug Evaluation, 361
research partnerships, 417	regulation of biotechnology products, 360
selected agreements, 574	U.S. General Accounting Office, 361, 372
tangible research property, 420	U.S. International Trade Commission, 391, 467
university policies, 580-584	U.S. Naval Research Laboratory, 315, 316
University of British Columbia, 244	U.S. Navy, 315
University of California, Berkeley, 384, 411, 413, 418,	U.S. Nuclear Regulatory Commission, 314
420	U.S. Office of Management and Budget, 92, 419
University of California, Davis, 415, 421	U.S. Patent and Trademark Office, 386, 389, 390, 403,
University of California, San Diego, 149, 420	459
University of California, San Francisco, 127, 137, 413	U.S. semiconductor industry and biotechnology, a com-
University of Geneva, 222	parison, 531-541
University of ~.orgia, 229	Bell Telephone Labs, 532
University of Gottingen, 222	development of U.S. industry, 532
University of Lueven (Belgium), 135	role of universities, 536
University of North Carolina, 244	role of U.S. Government, 533
University of Pennsylvania, 144	semiconductor devices, terminology and evaluation,
University of Virginia, 341	531
University of Washington, 144, 149, 418, 574	structure of U.S. industry, 537
University of Wisconsin, 411, 412	U.S. Small Business Administration, 91, 313
Upjohn Pharmaceuticals, 133	Set Aside Program, 316
U.S. Agency for International Development (AID), 26,	U.S. Supreme Court, 374, 386, 391, 400, 439
142	U. S. S. R., 204, 527
U.S. Air Force, 315	, ,
U.S. Army, 315	Valentine, Ray, 421
U.S. competitiveness, 7, 8	Varian Co., 88
antitrust laws, 18	Vega Biotechnologies, 84, 87
commitment to basic research, 14	Vellucci, Alfred, 489
intellectual property system, 17	• •, • •,
NBFs, 11	Wang, Prof. Daniel, 344
patent law, 16	Ward, Dr. David C., 148, 149
training of personnel, 15	Washington, 384
U.S. Department of Agriculture, 164, 238, 310, 314, 347,	Waters Technologies, 88
360, 373	Wisconsin Alumni Research Foundation, 411
Plum Island Animal Disease Facility, 164	Wellcome Research Laboratories (U.K.), 12, 75, 164
venture capital, 12, 71	Whitehead, Edwin C., 575
U.S. Department of Commerce, 200, 455, 457, 468	Whitehead Institute, 418, 575
U.S. Department of Defense (DOD), 254, 310, 312, 313,	White House Office of Science and Technology Policy,
314, 316, 327, 415, 457	458
Defense Advanced Research Projects Agency, 312, 315	World Health Organization (WHO), 142
Defense Business Advanced Technologies, 314	W. R. Grace, 196, 228
U.S. Department of Energy (DOE), 228, 247, 310, 312,	
314, 316, 349	Xoma Co., 94
U.S. Department of Health and Human Services, 315	- · · ·
Public Health Service, 315	Yale University School of Medicine, 148
U.S. Department of the Interior, 228, 314	Yankelovich, Skelly, and White, survey, 497